Novel Alzheimer’s disease blood‐based biomarkers in exercise trials
Thomas K Karikari, Kirk I Erickson, Irene Esteban‐Cornejo · 2025
Read Novel Alzheimer’s disease blood‐based biomarkers in exercise trials by Thomas K Karikari, Kirk I Erickson, Irene Esteban‐Cornejo (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11716138.txt.
Description
Thomas Karikari, Kirk Erickson, and Irene Esteban-Cornejo review what new blood tests can show inside exercise trials for Alzheimer's disease, in a 2025 paper. Regular exercise lowers the risk of the disease, but whether it changes the disease process itself is unknown. Blood markers now let trial teams watch brain-related changes without scans or spinal taps. The authors sum up early marker results from two large exercise trials.
One trial, IGNITE, ran for twelve months at several United States sites with over 600 healthy adults aged sixty-five to eighty. It split them into three levels of exercise dose. The second, AGUEDA, ran for twenty-four weeks in Spain with 90 healthy adults of the same age range. Both trials drew blood at the start and end, so marker shifts can be matched against exercise dose and time.
Catalog record
| CREATOR | Thomas K Karikari, Kirk I Erickson, Irene Esteban‐Cornejo |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |